Can Hasdemir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Can Hasdemir has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
Serdar Payzin
Department of Cardiology, Ege University School of Medicine, Izmir, Turkey
12 shared publicationsMehmet Aydin
Tepecik Teaching and Research Hospital, Izmir, Turkey
7 shared publicationsLevent H. Can
Department of Cardiology Ege University School of Medicine Izmir Turkey
6 shared publicationsHatice Sahin
Department of Cardiology, Ege University School of Medicine, Izmir, Turkey
5 shared publicationsMehmet N. Orman
Department of Biostatistics and Medical Informatics Ege University School of Medicine İzmir Türkiye
5 shared publicationsAlper Yuksel
Department of Biostatistics and Medical Informatics, Ege University School of Medicine, Izmir, Turkey; Kent Hospital, Izmir, Turkey
4 shared publications
Latest Publications
- 26 July 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (11) , 2565-2575
Phenomapping in Atrioventricular Nodal Reentrant Tachycardia: Mechanistic Insights and Therapeutic Implications
Background: Traditional classifications of atrioventricular nodal reentrant tachycardia (AVNRT) based on cardiac symptomatology, electrocardiographic findings, and reentrant circuits do not capture the full heterogeneity of AVNRT. Objective: This study sought to identify distinct phenotypes among patients with AVNRT by using two‐step cluster analysis and to determine differential effects of phenotypes on clinical and procedural outcomes. Methods: All patients ( n = 305) underwent catheter ablation and ajmaline challenge testing. A two‐step cluster analysis was conducted using 17 demographic/clinical, anthropometric, electrocardiographic, echocardiographic, and anatomic variables. Results: Three distinct clinically and mechanistically relevant clusters were identified. Cluster 1 (Metabolic/Structural Phenotype, n = 44) patients were characterized by older age of onset of AVNRT (53.5 ± 8.5, 43.5 ± 15, and 24.7 ± 10.5 years, p = 4.9 × 10 −31 ), shorter distance between coronary sinus floor and His bundle potential (22.7 ± 6.1, 24.7 ± 6.8, and 29 ± 7.5 mm, p = 1.3 × 10 −7 ), higher prevalence of “correlated” (diagnosed ≥ 4 years before AVNRT onset) type 2 diabetes (100%, 0%, and 0%, p = 5.9 × 10 −67 ) and “correlated” (diagnosed ≥ 6 years before AVNRT onset) structural heart disease (86.4%, 100%, 0%, p = 3.5 × 10 −62 ) compared to Cluster 2 (Structural Phenotype, n = 78) and Cluster 3 (Anatomic/Genetic Phenotype, n = 183) patients, respectively. Cluster 1 patients had higher prevalence of “pro‐arrhythmia” (new‐onset and/or symptom worsening/intolerance) with anti‐arrhythmic therapy and/or non‐cardiac drugs (74.2%, 46.5%, and 31.6%, p = 1.5 × 10 −4 ), AH prolongation/AV‐VA block (20.5%, 7.7%, and 2.2%, p = 8.9 × 10 −5 ) and aborted ablation (11.4%, 1.3%, and 0%, p = 8.6 × 10 −5 ) during EP study compared to Clusters 2 and 3 patients, respectively. Conclusion: Phenomapping identified three clinically and mechanistically relevant phenotypes of AVNRT associated with clinical and procedural outcomes, underscoring the considerable heterogeneity of AVNRT and the importance of comorbidities and substrates.
- 26 July 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (11) , 2565-2575
Phenomapping in Atrioventricular Nodal Reentrant Tachycardia: Mechanistic Insights and Therapeutic Implications
Background: Traditional classifications of atrioventricular nodal reentrant tachycardia (AVNRT) based on cardiac symptomatology, electrocardiographic findings, and reentrant circuits do not capture the full heterogeneity of AVNRT. Objective: This study sought to identify distinct phenotypes among patients with AVNRT by using two‐step cluster analysis and to determine differential effects of phenotypes on clinical and procedural outcomes. Methods: All patients ( n = 305) underwent catheter ablation and ajmaline challenge testing. A two‐step cluster analysis was conducted using 17 demographic/clinical, anthropometric, electrocardiographic, echocardiographic, and anatomic variables. Results: Three distinct clinically and mechanistically relevant clusters were identified. Cluster 1 (Metabolic/Structural Phenotype, n = 44) patients were characterized by older age of onset of AVNRT (53.5 ± 8.5, 43.5 ± 15, and 24.7 ± 10.5 years, p = 4.9 × 10 −31 ), shorter distance between coronary sinus floor and His bundle potential (22.7 ± 6.1, 24.7 ± 6.8, and 29 ± 7.5 mm, p = 1.3 × 10 −7 ), higher prevalence of “correlated” (diagnosed ≥ 4 years before AVNRT onset) type 2 diabetes (100%, 0%, and 0%, p = 5.9 × 10 −67 ) and “correlated” (diagnosed ≥ 6 years before AVNRT onset) structural heart disease (86.4%, 100%, 0%, p = 3.5 × 10 −62 ) compared to Cluster 2 (Structural Phenotype, n = 78) and Cluster 3 (Anatomic/Genetic Phenotype, n = 183) patients, respectively. Cluster 1 patients had higher prevalence of “pro‐arrhythmia” (new‐onset and/or symptom worsening/intolerance) with anti‐arrhythmic therapy and/or non‐cardiac drugs (74.2%, 46.5%, and 31.6%, p = 1.5 × 10 −4 ), AH prolongation/AV‐VA block (20.5%, 7.7%, and 2.2%, p = 8.9 × 10 −5 ) and aborted ablation (11.4%, 1.3%, and 0%, p = 8.6 × 10 −5 ) during EP study compared to Clusters 2 and 3 patients, respectively. Conclusion: Phenomapping identified three clinically and mechanistically relevant phenotypes of AVNRT associated with clinical and procedural outcomes, underscoring the considerable heterogeneity of AVNRT and the importance of comorbidities and substrates.
- Open Access
- 6 May 2022
- Published by Wiley in Journal of Arrhythmia
- Vol. 38 (4) , 633-641
Electrocardiographic variables associated with underlying Brugada syndrome or drug‐induced Type 1 Brugada pattern in patients with slow/fast atrioventricular nodal reentrant tachycardia
Background: The coexistence of clinical atrioventricular nodal reentrant tachycardia (AVNRT) and drug‐induced type 1 Brugada pattern (DI‐Type 1 BrP) has been previously reported. The present study was designed to determine the 12‐lead ECG characteristics at baseline and during AVNRT and to identify a subset of 12‐lead ECG variables of benefit associated with underlying Brugada syndrome (BrS)/DI‐Type 1 BrP among patients with slow/fast AVNRT.Methods: A total of 40 (11 numerical/29 categorical) 12‐lead ECG parameters were analyzed and compared between patients with (n = 69) and without (n = 104) BrS/DI‐Type1‐BrP matched for age, female gender, body mass index, left ventricular ejection fraction and comorbid conditions. Five distinct types of ECG pattern (Type A/B/C/D/E) in V1–V2 leads during AVNRT were defined.Results: A total of nine electrocardiographic variables, four at baseline, and five during AVNRT were identified. At baseline, patients with BrS/DI‐Type 1 BrP had higher prevalence of interatrial block, leftward shift of frontal plane QRS axis, the absence of normal QRS pattern (the presence of rSr’ pattern or type 2/3 Brugada pattern) in V1–V2 and QRS fragmentation in inferior leads compared to patients without BrS/DI‐Type 1 BrP. During AVNRT, patients with BrS/DI‐Type 1 BrP had higher prevalence of Type A ECG pattern (“coved‐type” ST‐segment elevation) in V1–V2, Type C ECG pattern (pseudo‐r’ deflection in V1 and “RBBB‐like” pattern in V2), pseudo‐r’ deflection in V1, QRS fragmentation in inferior leads and “isolated” QRS fragmentation/notching/slurring in aVL compared to patients without BrS/DI‐Type 1 BrP.Conclusions: We identify several electrocardiographic variables that point to an underlying type 1 BrP among patients with slow/fast AVNRT.
- 6 May 2022
- Published by Wiley in Journal of Arrhythmia
- Vol. 38 (4) , 633-641
Open AccessElectrocardiographic variables associated with underlying Brugada syndrome or drug‐induced Type 1 Brugada pattern in patients with slow/fast atrioventricular nodal reentrant tachycardia
Background: The coexistence of clinical atrioventricular nodal reentrant tachycardia (AVNRT) and drug‐induced type 1 Brugada pattern (DI‐Type 1 BrP) has been previously reported. The present study was designed to determine the 12‐lead ECG characteristics at baseline and during AVNRT and to identify a subset of 12‐lead ECG variables of benefit associated with underlying Brugada syndrome (BrS)/DI‐Type 1 BrP among patients with slow/fast AVNRT.Methods: A total of 40 (11 numerical/29 categorical) 12‐lead ECG parameters were analyzed and compared between patients with (n = 69) and without (n = 104) BrS/DI‐Type1‐BrP matched for age, female gender, body mass index, left ventricular ejection fraction and comorbid conditions. Five distinct types of ECG pattern (Type A/B/C/D/E) in V1–V2 leads during AVNRT were defined.Results: A total of nine electrocardiographic variables, four at baseline, and five during AVNRT were identified. At baseline, patients with BrS/DI‐Type 1 BrP had higher prevalence of interatrial block, leftward shift of frontal plane QRS axis, the absence of normal QRS pattern (the presence of rSr’ pattern or type 2/3 Brugada pattern) in V1–V2 and QRS fragmentation in inferior leads compared to patients without BrS/DI‐Type 1 BrP. During AVNRT, patients with BrS/DI‐Type 1 BrP had higher prevalence of Type A ECG pattern (“coved‐type” ST‐segment elevation) in V1–V2, Type C ECG pattern (pseudo‐r’ deflection in V1 and “RBBB‐like” pattern in V2), pseudo‐r’ deflection in V1, QRS fragmentation in inferior leads and “isolated” QRS fragmentation/notching/slurring in aVL compared to patients without BrS/DI‐Type 1 BrP.Conclusions: We identify several electrocardiographic variables that point to an underlying type 1 BrP among patients with slow/fast AVNRT.
- 24 May 2021
- Published by Elsevier in The American Journal of Cardiology
- Vol. 151, 51-56
Frequency of Irritable Bowel Syndrome in Patients with Brugada Syndrome and Drug-Induced Type 1 Brugada Pattern
- 24 May 2021
- Published by Elsevier in The American Journal of Cardiology
- Vol. 151, 51-56
Frequency of Irritable Bowel Syndrome in Patients with Brugada Syndrome and Drug-Induced Type 1 Brugada Pattern
- 23 October 2020
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 31 (12) , 3311-3317
Recognition and clinical implications of high prevalence of migraine in patients with Brugada syndrome and drug‐induced type 1 Brugada pattern
Introduction: We have previously reported high 1‐year prevalence of migraine in patients with atrial arrhythmias associated with DI‐type 1 BrP. The present study was designed to determine the lifetime prevalence of migraine in patients with Brugada syndrome (BrS) or drug‐induced type 1 Brugada pattern (DI‐type 1 BrP) and control group, to investigate the demographic and clinical characteristics, and to identify clinical variables to predict underlying BrS/DI‐type 1 BrP among migraineurs.Methods and Results: Lifetime prevalence of migraine and migraine characteristics were compared between probands with BrS/DI‐type 1 BrP (n = 257) and control group (n = 370). Lifetime prevalence of migraine was 60.7% in patients with BrS/DI‐type 1 BrP and 30.3% in control group (p = 3.6 × 10−14). On stepwise regression analysis, familial migraine (odds ratio [OR] of 4.4; 95% confidence interval [CI]: 2.0–9.8; p = 1.3 × 10−4), vestibular migraine (OR of 5.4; 95% CI: 1.4–21.0); p = .013), migraine with visual aura (OR of 1.8; 95% CI: 1.0–3.4); p = .04) and younger age‐at‐onset of migraine (OR of 0.95; 95% CI: 0.93–0.98); p = .004) were predictors of underlying BrS/DI‐type 1 BrP among migraineurs. Use of anti‐migraine drugs classified as “to be avoided” or “preferably avoided” in patients with BrS and several other anti‐migraine drugs with potential cardiac INa/ICa channel blocking properties was present in 25.6% and 26.9% of migraineurs with BrS/DI‐type 1 BrP, respectively.Conclusion: Migraine comorbidity is common in patients with BrS/DI‐type 1 BrP. We identify several clinical variables that point to an underlying type‐1 BrP among migraineurs, necessitating cautious use of certain anti‐migraine drugs.
- 23 October 2020
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 31 (12) , 3311-3317
Recognition and clinical implications of high prevalence of migraine in patients with Brugada syndrome and drug‐induced type 1 Brugada pattern
Introduction: We have previously reported high 1‐year prevalence of migraine in patients with atrial arrhythmias associated with DI‐type 1 BrP. The present study was designed to determine the lifetime prevalence of migraine in patients with Brugada syndrome (BrS) or drug‐induced type 1 Brugada pattern (DI‐type 1 BrP) and control group, to investigate the demographic and clinical characteristics, and to identify clinical variables to predict underlying BrS/DI‐type 1 BrP among migraineurs.Methods and Results: Lifetime prevalence of migraine and migraine characteristics were compared between probands with BrS/DI‐type 1 BrP (n = 257) and control group (n = 370). Lifetime prevalence of migraine was 60.7% in patients with BrS/DI‐type 1 BrP and 30.3% in control group (p = 3.6 × 10−14). On stepwise regression analysis, familial migraine (odds ratio [OR] of 4.4; 95% confidence interval [CI]: 2.0–9.8; p = 1.3 × 10−4), vestibular migraine (OR of 5.4; 95% CI: 1.4–21.0); p = .013), migraine with visual aura (OR of 1.8; 95% CI: 1.0–3.4); p = .04) and younger age‐at‐onset of migraine (OR of 0.95; 95% CI: 0.93–0.98); p = .004) were predictors of underlying BrS/DI‐type 1 BrP among migraineurs. Use of anti‐migraine drugs classified as “to be avoided” or “preferably avoided” in patients with BrS and several other anti‐migraine drugs with potential cardiac INa/ICa channel blocking properties was present in 25.6% and 26.9% of migraineurs with BrS/DI‐type 1 BrP, respectively.Conclusion: Migraine comorbidity is common in patients with BrS/DI‐type 1 BrP. We identify several clinical variables that point to an underlying type‐1 BrP among migraineurs, necessitating cautious use of certain anti‐migraine drugs.
- 28 June 2018
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 41 (9) , 1078-1092
Coexistence of atrioventricular accessory pathways and drug‐induced type 1 Brugada pattern
Background: Atrial arrhythmias, particularly atrioventricular nodal reentrant tachycardia, can coexist with drug‐induced type 1 Brugada electrocardiogram (ECG) pattern (DI‐Type1‐BrP). The present study was designed to determine the prevalence of DI‐Type1‐BrP in patients with atrioventricular accessory pathways (AV‐APs) and to investigate the clinical, electrocardiographic, electrophysiologic, and genetic characteristics of these patients.Methods: One‐hundred twenty‐four consecutive cases of AV‐APs and 84 controls underwent an ajmaline challenge test to unmask DI‐Type1‐BrP. Genetic screening and analysis was performed in 55 of the cases (19 with and 36 without DI‐Type1‐BrP).Results: Patients with AV‐APs were significantly more likely than controls to have a Type1‐BrP unmasked (16.1 vs 4.8%, P = 0.012). At baseline, patients with DI‐Type1‐BrP had higher prevalence of chest pain, QR/rSr’ pattern in V1 and QRS notching/slurring in V2 and aVL during preexcitation, rSr’ pattern in V1‐V2, and QRS notching/slurring in aVL during orthodromic atrioventricular reentrant tachycardia (AVRT) compared to patients without DI‐Type1‐BrP. Abnormal QRS configuration (QRS notching/slurring and/or fragmentation) in V2 during preexcitation was present in all patients with DI‐Type1 BrP. The prevalence of spontaneous preexcited atrial fibrillation (AF) and history of AF were similar (15% vs 18.3%, P = 0.726) in patients with and without DI‐Type1‐BrP, respectively. The prevalence of mutations in Brugada‐susceptibility genes was higher (36.8% vs 8.3%, P = 0.02) in patients with DI‐Type1‐BrP compared to patients without DI‐Type1‐BrP.Conclusions: DI‐Type1‐BrP is relatively common in patients with AV‐APs. We identify 12‐lead ECG characteristics during preexcitation and orthodromic AVRT that point to an underlying type1‐BrP, portending an increased probability for development of malignant arrhythmias.
- 28 June 2018
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 41 (9) , 1078-1092
Coexistence of atrioventricular accessory pathways and drug‐induced type 1 Brugada pattern
Background: Atrial arrhythmias, particularly atrioventricular nodal reentrant tachycardia, can coexist with drug‐induced type 1 Brugada electrocardiogram (ECG) pattern (DI‐Type1‐BrP). The present study was designed to determine the prevalence of DI‐Type1‐BrP in patients with atrioventricular accessory pathways (AV‐APs) and to investigate the clinical, electrocardiographic, electrophysiologic, and genetic characteristics of these patients.Methods: One‐hundred twenty‐four consecutive cases of AV‐APs and 84 controls underwent an ajmaline challenge test to unmask DI‐Type1‐BrP. Genetic screening and analysis was performed in 55 of the cases (19 with and 36 without DI‐Type1‐BrP).Results: Patients with AV‐APs were significantly more likely than controls to have a Type1‐BrP unmasked (16.1 vs 4.8%, P = 0.012). At baseline, patients with DI‐Type1‐BrP had higher prevalence of chest pain, QR/rSr’ pattern in V1 and QRS notching/slurring in V2 and aVL during preexcitation, rSr’ pattern in V1‐V2, and QRS notching/slurring in aVL during orthodromic atrioventricular reentrant tachycardia (AVRT) compared to patients without DI‐Type1‐BrP. Abnormal QRS configuration (QRS notching/slurring and/or fragmentation) in V2 during preexcitation was present in all patients with DI‐Type1 BrP. The prevalence of spontaneous preexcited atrial fibrillation (AF) and history of AF were similar (15% vs 18.3%, P = 0.726) in patients with and without DI‐Type1‐BrP, respectively. The prevalence of mutations in Brugada‐susceptibility genes was higher (36.8% vs 8.3%, P = 0.02) in patients with DI‐Type1‐BrP compared to patients without DI‐Type1‐BrP.Conclusions: DI‐Type1‐BrP is relatively common in patients with AV‐APs. We identify 12‐lead ECG characteristics during preexcitation and orthodromic AVRT that point to an underlying type1‐BrP, portending an increased probability for development of malignant arrhythmias.
- 28 June 2016
- Published by Springer Nature
- p. 245-258
Atrial Arrhythmias Associated with J Wave Syndromes
- 28 June 2016
- Published by Springer Nature
- p. 245-258
Atrial Arrhythmias Associated with J Wave Syndromes
- Open Access
- 9 February 2016
- Published by Wiley in Journal of Arrhythmia
- Vol. 32 (5) , 366-372
Atrial arrhythmias in inherited arrhythmogenic disorders
Atrial arrhythmias are being increasingly recognized in inherited arrhythmogenic disorders particularly in patients with Brugada syndrome and short QT syndrome. Atrial arrhythmias in inherited arrhythmogenic disorders have significant epidemiologic, clinical, and prognostic implications. There has been progress in the understanding of underlying genetic characteristics and the mechanistic link between atrial arrhythmias and inherited arrhythmogenic disorders. Appropriate management of these patients is of paramount importance.
- 9 February 2016
- Published by Wiley in Journal of Arrhythmia
- Vol. 32 (5) , 366-372
Open AccessAtrial arrhythmias in inherited arrhythmogenic disorders
Atrial arrhythmias are being increasingly recognized in inherited arrhythmogenic disorders particularly in patients with Brugada syndrome and short QT syndrome. Atrial arrhythmias in inherited arrhythmogenic disorders have significant epidemiologic, clinical, and prognostic implications. There has been progress in the understanding of underlying genetic characteristics and the mechanistic link between atrial arrhythmias and inherited arrhythmogenic disorders. Appropriate management of these patients is of paramount importance.
- 1 July 2015
- Published by Elsevier in Heart Rhythm
- Vol. 12 (7) , 1584-1594
High prevalence of concealed Brugada syndrome in patients with atrioventricular nodal reentrant tachycardia
- 1 July 2015
- Published by Elsevier in Heart Rhythm
- Vol. 12 (7) , 1584-1594
High prevalence of concealed Brugada syndrome in patients with atrioventricular nodal reentrant tachycardia